Successful Dupilumab Treatment of Atopic Dermatitis in a Liver Transplant Patient

Main Article Content

Amanda Krenitsky
University of South Florida

Sairekha Ravichandran
Joel Cohen
USF Health, Morsani College of Medicine

Jonathan Braue
Lilia Correa-Selm
University of South Florida

Keywords

Transplant, Dupixent, Dupilumab, Atopic Dermatitis, scaly, AD

Abstract

Atopic dermatitis (AD) in liver transplant (LT) recipients is well-documented, despite frequent use of immunosuppressants in these patients. In a liver transplant population, the prevalence of AD in children and adults is 27.6% and 10.3%, respectively.1 However, there is dearth ofliterature regardingtreatment of this population, and standard regimens are not well-defined.2-4 Here, we report a case of successful treatment of AD in an orthotopic LT patient with dupilumab. 

References

1. Topal E, Çatal F, Selimoğlu MA, et al. Acquired atopic disease after liver transplantation in children; similarities to and differences from adults: a preliminary study. Eur J Gastroenterol Hepatol. Sep 2014;26(9):1055-9. doi:10.1097/meg.0000000000000142

2. Ludriksone L, Elsner P, Malessa C, Settmacher U, Schliemann S. Effectiveness and safety of dupilumab for atopic dermatitis in a liver transplant recipient: a case report. J Dtsch Dermatol Ges. Jul 2020;18(7):740-742. doi:10.1111/ddg.14074

3. Kha C, Raji K, Chisolm S. Treatment of Atopic Dermatitis With Dupilumab in a Renal Transplant Patient. Dermatitis. Mar/Apr 2020;31(2):e17-e18. doi:10.1097/der.0000000000000560

4. Jamgochian M, Milgraum D, Milgraum S, Pappert A. Dupilumab as treatment for atopic dermatitis in a pediatric heart transplant patient: A case report. Dermatol Ther. Nov 2020;33(6):e14018. doi:10.1111/dth.14018

5. Tsianakas A, Ständer S. Dupilumab: a milestone in the treatment of atopic dermatitis. Lancet. Jan 2 2016;387(10013):4-5. doi:10.1016/s0140-6736(15)00389-x

6. Product Approval Information - Licensing Action Dupixent (dupilumab). Available online at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761055lbl.pdf (accessed on 06 Sep 2021).

Article Sidebar

PDF
Published
Mar 4, 2022
DOI https://doi.org/10.25251/skin.6.2.7

Article Details

How to Cite
Krenitsky, A., Ravichandran, S., Cohen, J., Braue, J., & Correa-Selm, L. (2022). Successful Dupilumab Treatment of Atopic Dermatitis in a Liver Transplant Patient . SKIN The Journal of Cutaneous Medicine, 6(2), 135–137. https://doi.org/10.25251/skin.6.2.7
Issue
Vol. 6 No. 2 (2022): March Issue and Poster Presentations (FC PANP 21 and WC 22 Dermatology Conferences®)
Section
Brief Articles
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by  the following user license:
 

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation. 

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.